Real-World Anti-Vascular Endothelial Growth Factor Therapy Outcomes in Myopic Choroidal Neovascularization

Devangna Bhatia, Alexander Mehta, Joanna DaCosta, Oonagh Crothers, James Stephen Talks Newcastle Eye Centre, Royal Victoria Infirmary, Newcastle upon Tyne, UKCorrespondence: Devangna BhatiaNewcastle Eye Centre, Royal Victoria Infirmary, Newcastle upon Tyne, UKEmail Devangna88@gmail.comAim: Evaluatio...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bhatia D, Mehta A, DaCosta J, Crothers O, Talks JS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	myopia pathological myopia choroidal neovascularization anti-vegf intravitreal injection Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/8f47d93675f744c3861a108c77860a1a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8f47d93675f744c3861a108c77860a1a
record_format	dspace
spelling	oai:doaj.org-article:8f47d93675f744c3861a108c77860a1a2021-12-02T17:45:21ZReal-World Anti-Vascular Endothelial Growth Factor Therapy Outcomes in Myopic Choroidal Neovascularization1177-5483https://doaj.org/article/8f47d93675f744c3861a108c77860a1a2021-06-01T00:00:00Zhttps://www.dovepress.com/real-world-anti-vascular-endothelial-growth-factor-therapy-outcomes-in-peer-reviewed-fulltext-article-OPTHhttps://doaj.org/toc/1177-5483Devangna Bhatia, Alexander Mehta, Joanna DaCosta, Oonagh Crothers, James Stephen Talks Newcastle Eye Centre, Royal Victoria Infirmary, Newcastle upon Tyne, UKCorrespondence: Devangna BhatiaNewcastle Eye Centre, Royal Victoria Infirmary, Newcastle upon Tyne, UKEmail Devangna88@gmail.comAim: Evaluation of real-world outcomes of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy in the primary treatment of choroidal neovascularization (CNV) secondary to pathological myopia.Patients and Methods: A retrospective cohort analysis of treatment naive patients with myopic CNV who received treatment with either intravitreal ranibizumab or aflibercept over a 12-year period from September 2007 to May 2020 was performed. Baseline features, treatment factors and outcomes were compared between younger and older patients and final visual outcome was assessed for associated factors.Results: Thirty-seven eyes of 36 patients (24 females, 12 males) were included. Mean age was 58 years (range=26– 89 years). Of these patients, 11/36 (31%) were ≤ 50 years of age and 25/36 (69%) were ≥ 51 years of age. Seventy-three percent (27/37) of eyes were phakic. One patient received bilateral treatment for myopic CNV. Median spherical equivalent was − 8.50 diopters. Seventy percent (26/37) of eyes commenced primary treatment with ranibizumab, and 11/37 (30%) eyes commenced treatment with aflibercept. There were no significant differences between treatment factors and outcomes of younger and older patients. Median number of injections was 3 over a median follow-up period of 24.6 months. Mean CRT decreased by 126μm and median visual improvement was +6 letters. Analysis showed that younger age (p=0.022) and fewer injections (p=0.004) were associated with better visual outcomes.Conclusion: Myopic CNV requires less frequent anti-VEGF intravitreal therapy over a shorter follow-up period than both neovascular age-related macular degeneration and diabetic macular edema. Increased frequency of administration of intravitreal anti-VEGF treatment did not improve vision. Younger age is associated with a better final visual outcome. These findings may help to advise patients about the prognosis of treatment and help guide treatment decisions.Keywords: myopia, pathological myopia, choroidal neovascularization, anti-VEGF intravitreal injectionBhatia DMehta ADaCosta JCrothers OTalks JSDove Medical Pressarticlemyopiapathological myopiachoroidal neovascularizationanti-vegf intravitreal injectionOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 15, Pp 2753-2758 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	myopia pathological myopia choroidal neovascularization anti-vegf intravitreal injection Ophthalmology RE1-994
spellingShingle	myopia pathological myopia choroidal neovascularization anti-vegf intravitreal injection Ophthalmology RE1-994 Bhatia D Mehta A DaCosta J Crothers O Talks JS Real-World Anti-Vascular Endothelial Growth Factor Therapy Outcomes in Myopic Choroidal Neovascularization
description	Devangna Bhatia, Alexander Mehta, Joanna DaCosta, Oonagh Crothers, James Stephen Talks Newcastle Eye Centre, Royal Victoria Infirmary, Newcastle upon Tyne, UKCorrespondence: Devangna BhatiaNewcastle Eye Centre, Royal Victoria Infirmary, Newcastle upon Tyne, UKEmail Devangna88@gmail.comAim: Evaluation of real-world outcomes of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy in the primary treatment of choroidal neovascularization (CNV) secondary to pathological myopia.Patients and Methods: A retrospective cohort analysis of treatment naive patients with myopic CNV who received treatment with either intravitreal ranibizumab or aflibercept over a 12-year period from September 2007 to May 2020 was performed. Baseline features, treatment factors and outcomes were compared between younger and older patients and final visual outcome was assessed for associated factors.Results: Thirty-seven eyes of 36 patients (24 females, 12 males) were included. Mean age was 58 years (range=26– 89 years). Of these patients, 11/36 (31%) were ≤ 50 years of age and 25/36 (69%) were ≥ 51 years of age. Seventy-three percent (27/37) of eyes were phakic. One patient received bilateral treatment for myopic CNV. Median spherical equivalent was − 8.50 diopters. Seventy percent (26/37) of eyes commenced primary treatment with ranibizumab, and 11/37 (30%) eyes commenced treatment with aflibercept. There were no significant differences between treatment factors and outcomes of younger and older patients. Median number of injections was 3 over a median follow-up period of 24.6 months. Mean CRT decreased by 126μm and median visual improvement was +6 letters. Analysis showed that younger age (p=0.022) and fewer injections (p=0.004) were associated with better visual outcomes.Conclusion: Myopic CNV requires less frequent anti-VEGF intravitreal therapy over a shorter follow-up period than both neovascular age-related macular degeneration and diabetic macular edema. Increased frequency of administration of intravitreal anti-VEGF treatment did not improve vision. Younger age is associated with a better final visual outcome. These findings may help to advise patients about the prognosis of treatment and help guide treatment decisions.Keywords: myopia, pathological myopia, choroidal neovascularization, anti-VEGF intravitreal injection
format	article
author	Bhatia D Mehta A DaCosta J Crothers O Talks JS
author_facet	Bhatia D Mehta A DaCosta J Crothers O Talks JS
author_sort	Bhatia D
title	Real-World Anti-Vascular Endothelial Growth Factor Therapy Outcomes in Myopic Choroidal Neovascularization
title_short	Real-World Anti-Vascular Endothelial Growth Factor Therapy Outcomes in Myopic Choroidal Neovascularization
title_full	Real-World Anti-Vascular Endothelial Growth Factor Therapy Outcomes in Myopic Choroidal Neovascularization
title_fullStr	Real-World Anti-Vascular Endothelial Growth Factor Therapy Outcomes in Myopic Choroidal Neovascularization
title_full_unstemmed	Real-World Anti-Vascular Endothelial Growth Factor Therapy Outcomes in Myopic Choroidal Neovascularization
title_sort	real-world anti-vascular endothelial growth factor therapy outcomes in myopic choroidal neovascularization
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/8f47d93675f744c3861a108c77860a1a
work_keys_str_mv	AT bhatiad realworldantivascularendothelialgrowthfactortherapyoutcomesinmyopicchoroidalneovascularization AT mehtaa realworldantivascularendothelialgrowthfactortherapyoutcomesinmyopicchoroidalneovascularization AT dacostaj realworldantivascularendothelialgrowthfactortherapyoutcomesinmyopicchoroidalneovascularization AT crotherso realworldantivascularendothelialgrowthfactortherapyoutcomesinmyopicchoroidalneovascularization AT talksjs realworldantivascularendothelialgrowthfactortherapyoutcomesinmyopicchoroidalneovascularization
_version_	1718379600707321856

Real-World Anti-Vascular Endothelial Growth Factor Therapy Outcomes in Myopic Choroidal Neovascularization

Ejemplares similares